Table 2.

Connectivity Map results showing the congruence of the common PPFP profile and gene expression changes caused by pioglitazone treatment.

rank	cmap name	dose	cell	score	up	down
111	pioglitazone	10 µM	PC3	0.841	0.393	−0.743
228	pioglitazone	10 µM	PC3	0.793	0.399	−0.672
259	pioglitazone	10 µM	PC3	0.786	0.245	−0.817
501	pioglitazone	10 µM	MCF7	0.73	0.308	−0.678
599	pioglitazone	10 µM	MCF7	0.713	0.139	−0.824
648	pioglitazone	10 µM	PC3	0.705	0.277	−0.676
1141	pioglitazone	10 µM	PC3	0.625	0.222	−0.623
2191	pioglitazone	10 µM	MCF7	0	0.236	0.598
2240	pioglitazone	10 µM	MCF7	0	0.229	0.718
3349	pioglitazone	10 µM	MCF7	0	−0.118	−0.681
5816	pioglitazone	10 µM	MCF7	−0.783	−0.144	0.89

Each row represents a CMAP instance - a treatment and control pair subjected to gene expression profiling to derive a set of differentially expressed genes. The score is a value between 1 and −1 indicating the level of overlap between a CMAP instance and the query signature. A high positive score indicates a treatment which induced a set of gene expression changes similar to the query. A low negative score indicates a treatment which reversed the gene expression changes in the query. A 0 score indicates no self-consistent correlation between the two sets. The up and down columns indicate the enrichment scores for the induced and repressed gene set, respectively. Considering all 11 instances together, pioglitazone induced genes were enriched in the common PPFP profile (p = 0.014, as calculated by CMAP).